Core Viewpoint - The company is expected to see continued profit growth in Q2 2025, driven by positive business performance and the upcoming launch of Yu7 in July 2025, which serves as a catalyst for growth [1]. Financial Performance - In Q1 2025, the company's non-GAAP net profit reached 10.7 billion, a year-on-year increase of 64.5%, exceeding expectations due to better-than-expected gross margins in IoT and automotive sectors [1]. - The core business profit was 11.2 billion, while the automotive and new business incurred a loss of 0.5 billion [1]. - The company sold 41.8 million smartphones, a 2% quarter-on-quarter decline, primarily due to weak demand in overseas markets like India [1]. Revenue Breakdown - The average selling price (ASP) increased by 6% year-on-year and 1% quarter-on-quarter, benefiting from improved product mix [2]. - Smartphone gross margin decreased by 2.4 percentage points to 12.4% year-on-year due to rising costs of core components, but improved by 0.4 percentage points quarter-on-quarter due to better product mix in overseas markets [2]. - IoT revenue reached 32.3 billion, a year-on-year increase of 59% and a quarter-on-quarter increase of 5%, driven by government subsidies and enhanced brand strength [2]. - The gross margin for IoT improved by 5.3 percentage points to 25.2% due to higher margins in major appliances and product mix improvements [2]. - Internet revenue was 9.1 billion, showing a quarter-on-quarter decline of 3%, with a gross margin of 76.9% [2]. - Automotive sales reached 76,000 units, with an ASP of 238,000, slightly up from 234,000 in Q4 2024, primarily driven by the SU7 ultra model [2]. - The automotive gross margin improved by 3 percentage points to 23% due to changes in product mix [2]. Future Outlook - The company is focusing on high-quality products in its smartphone business, with expectations for further ASP increases [2]. - IoT business revenue growth is anticipated to reach 30% in 2025, supported by enhanced brand strength and optimized product mix [2]. - The company expects to exceed 350,000 units in automotive deliveries for the year, with improved gross margins [2].

Core Viewpoint - Xiaomi Group reported record high revenue and adjusted net profit for Q1 2025, driven by strong performance in its smartphone and IOT segments, alongside a strategic focus on cost reduction and efficiency improvement [1][2][3] Financial Performance - Q1 2025 revenue reached 1112.93 billion, a year-over-year increase of 47.4% and a quarter-over-quarter increase of 2.1% [1] - Adjusted net profit for the same period was 106.76 billion, reflecting a year-over-year growth of 64.5% and a quarter-over-quarter growth of 28.4% [1] - Overall gross margin stood at 22.8%, with a year-over-year increase of 0.5 percentage points [1] Business Segments - The smartphone and AIOT segment generated revenue of 927.13 billion, a year-over-year increase of 22.8% [1] - The smart electric vehicle and AI innovation segment achieved revenue of 185.80 billion [1] - IOT business revenue surged to 323.39 billion, marking a year-over-year increase of 58.7% and contributing 29.1% to total revenue [2] - Internet services revenue reached 90.76 billion, with a year-over-year increase of 12.8% [2] Market Position - Xiaomi's smartphone shipments reached 41.8 million units in Q1 2025, a year-over-year increase of 3.0%, maintaining a global market share of 14.1% [2] - In mainland China, Xiaomi regained the top position in smartphone shipments with a market share of 18.8% [2] R&D and Future Outlook - The company plans to invest 2000 billion over the next five years in core technology development [3] - R&D expenditure for Q1 2025 was 67 billion, a year-over-year increase of 30.1% [3] - The launch of self-developed 3nm flagship SoC chip and the open-sourcing of the Xiaomi MiMo model are significant advancements [3] Investment Recommendation - The company is expected to benefit from its brand recognition and supply chain advantages, with projections for revenue and net profit growth from 2025 to 2027 [4] - Forecasted revenues for 2025, 2026, and 2027 are 5062.65 billion, 6052.13 billion, and 7008.88 billion respectively, with corresponding net profits of 357.09 billion, 457.75 billion, and 598.89 billion [4]

机构：平安证券 YU7 高举高打，配置相比SU7 有较大幅度提升。YU7 已经亮相，根据公司规划，YU7 预计将于7 月份 正式发布上市。根据公司披露的YU7 配置信息，YU7 将推出三个版本，标准版、Pro 和Max，且全系超 长续航，标准版即搭载96.3 度电池包，CLTC 续航里程达到835km。在其他配置方面，YU7 相比SU7 也 有较大幅度升级，如YU7 全系搭载英伟达Thor 平台和激光雷达，全系搭载小米天际屏全景显示，此 外，Pro 和Max 版本均搭载双电机四驱以及闭式双腔空簧。我们认为YU7 在配置方面相较SU7有较大幅 度提升，同时考虑到公司汽车产能依然紧张，因此我们认为YU7的定价会采取高举高打的策略，价格中 枢相较SU7 会有明显提升。 手机高端化战略推进，中国大陆市场份额排名重回第一。根据公司以及Canalys 披露，一季度公司手机 出货量、手机营收分别达到4180 万台/506亿元，智能手机ASP 达到1211 元（同比+5.8%）。市占率方 面，一季度公司智能手机全球市占率达到14.1%，居全球第三位，其中中国大陆地区市占率达到18.8% （同比+4.7 个百分点），市占率重回 ...

恒生科技指数盘初跌幅迅速扩大至2%，热门科网股普遍下挫，阿里巴巴(09988.HK)、京东 (09618.HK)、百度(09888.HK)、哔哩哔哩(09626.HK)均跌超3%，舜宇光学科技(02382.HK)、金山软件 (03888.HK)跌近4%。 ...

恒生科技指数跌幅扩大至2%，网易跌超5%，舜宇光学科技跌超4%。 ...

Core Viewpoint - The Hong Kong stock market is undergoing significant changes, with a focus on the AI industry and the influx of quality companies, which is expected to drive future growth and investment opportunities [2][4]. Group 1: Market Performance - The Hang Seng Index opened down 0.99%, while the Hang Seng Tech Index fell by 1.26% [1]. - The influx of capital from mainland China is strengthening pricing power in the Hong Kong market, with expectations of continued inflows [2]. Group 2: Investment Opportunities - The AI industry is anticipated to lead the Hong Kong stock market upward, benefiting from high capital expenditure and the accumulation of scarce assets [2]. - Quality Chinese assets are seen as a fundamental basis for the sustainable growth of the Hong Kong stock market [3]. - The valuation of Hong Kong stocks is recovering, with the Hang Seng Index's PE ratio rising from approximately 7.5 times to 10.5 times, indicating room for further appreciation compared to historical highs [3]. Group 3: IPO Trends - The Hong Kong IPO market is expected to see a significant revival in 2025, providing a crucial window for domestic companies to raise foreign capital [3]. - The trend of A-share companies listing in Hong Kong is driven by strategic overseas expansion, regulatory advantages, and improved liquidity in the Hong Kong market [4]. Group 4: Government Policies - The Hong Kong government has implemented several supportive policies for the stock market, including lowering stamp duties and optimizing trading mechanisms to enhance market liquidity and attractiveness [5].

港股稳定币概念股众安在线(06060.HK)继昨日大涨逾30%后今日盘初下挫，现跌2.61%。 ...

Core Viewpoint - CICC maintains the earnings forecast for CSPC Pharmaceutical Group (01093) for 2025 and 2026, with a target price increase of 26.5% to HKD 8.60, indicating a potential upside of 12.9% from the current stock price [1] Financial Performance - The company reported Q1 2025 results: revenue of CNY 7.015 billion (including BD revenue of CNY 718 million), down 21.9% YoY, but up 10.9% QoQ; net profit attributable to shareholders was CNY 1.478 billion (down 8.4% YoY, up 168.7% QoQ), and core net profit was CNY 1.411 billion (down 18.2% YoY, up 106.2% QoQ), aligning with CICC's expectations [2] Business Segment Analysis - Q1 2025 finished drug business faced pressure, with revenue of CNY 5.500 billion (down 27.3% YoY); specific segments included: CNS revenue CNY 1.908 billion (down 29.5% YoY), oncology CNY 552 million (down 65.7% YoY), anti-infection CNY 922 million (down 31.8% YoY), cardiovascular CNY 411 million (down 42.9% YoY), respiratory CNY 326 million (down 30.3% YoY), digestive metabolism CNY 299 million (down 4.7% YoY), and other finished drug products CNY 364 million (down 6.8% YoY); raw material drug revenue for Vitamin C was CNY 608 million (up 25.0% YoY) [3] Cost and Profitability Metrics - The company achieved a gross margin of 67.1% in Q1 2025 (down 5.2 percentage points YoY); the sales expense ratio improved to 23.7% (down 9.3 percentage points YoY), while the management expense ratio was 3.3% (down 0.4 percentage points YoY); R&D expense ratio was 23.7% (up 8.2 percentage points YoY), with expectations for annual R&D expenses to exceed CNY 5.5 billion [4] Innovation and Future Prospects - The company is optimistic about the clinical data readouts for key innovative products and the successful execution of BD transactions; SYS6010 (EGFR ADC) is under exploration with multiple clinical trials ongoing, and the company anticipates more significant BD transactions this year to enhance shareholder returns [5]

港股医药股走强 石药集团涨近8% 智通财经5月30日电，截至发稿，石药集团(01093.HK)涨7.61%、康哲药业(00867.HK)涨5.85%、信达生 物(01801.HK)涨3.86%、凯莱英(06821.HK)涨2.33%。 ...

智通财经5月30日电，利弗莫尔证券显示，手回集团香港上市首日低开超7%，报7.5港元，发行价为8.08 港元。 ...